Phase 3
Completed N=482
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Source: ClinicalTrials.gov NCT01252940 ↗Enrolled (actual)
482
Serious AEs
6.1%
Results posted
Apr 2013
Primary outcomePrimary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (FDA Snapshot Analysis) — 93.7; 89.9 percentage of participants
Summary
The purpose of this randomized, open-label, multicenter, active-controlled Phase 3b study is to evaluate the noninferiority of the emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) single-tablet regimen (STR; also referred to as fixed-dose regimen or fixed-dose tablet) relative to regimens consisting of a ritonavir-boosted protease inhibitor (PI+RTV) and two nucleoside reverse transcriptase inhibitors (NRTIs) in virologically suppressed, HIV-1 infected subjects. The FTC/RPV/TDF STR could offer an attractive treatment option to patients who wish to simplify dosing by reducing pill burden or to improve the tolerability of their treatment.
Participants will be randomized into 2 groups, the FTC/RPV/TDF STR group, in which participants will switch treatment regimens at the start of the study, and the Stay on Baseline Regimen (SBR)/Delayed Switch group, in which participants will remain on their baseline regimen during the first 24 weeks of the study (designed to provide an initial active control), and may switch to the FTC/RPV/TDF STR at the Week 24 visit.
After the 48-week study analysis period, participants may continue to receive the FTC/RPV/TDF STR per protocol before switching to a commercially available source.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 24 (FDA Snapshot Analysis) |
93.7; 89.9 | — |
| SECONDARY Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 (FDA Snapshot Analysis) |
89.3; 92.1 | — |
| SECONDARY Change From Baseline in Cluster of Differentiation 4 (CD4) Count Through Week 24 |
20; 32 | — |
| SECONDARY Change From Baseline in CD4 Count Through Week 48 |
10; -7 | — |
| SECONDARY Change From Baseline in Fasting Total Cholesterol Through Week 24 |
-25; -1 | — |
| SECONDARY Change From Baseline in Fasting Total Cholesterol Through Week 48 |
-24; -24 | — |
| SECONDARY Change From Baseline in Fasting High-density Lipoprotein (HDL) Cholesterol Through Week 24 |
-4; -1 | — |
| SECONDARY Change From Baseline in Fasting HDL Cholesterol Through Week 48 |
-2; -2 | — |
| SECONDARY Change From Baseline in Fasting Direct Low-density Lipoprotein (LDL) Cholesterol Through Week 24 |
-16; 0 | — |
| SECONDARY Change From Baseline in Fasting Direct LDL Cholesterol Through Week 48 |
-16; -14 | — |
| SECONDARY Change From Baseline in Fasting Triglycerides Through Week 24 |
-53; 3 | — |
| SECONDARY Change From Baseline in Fasting Triglycerides Through Week 48 |
-64; -80 | — |
Eligibility Criteria
Inclusion Criteria
- Ability to understand and sign a written informed consent form
- Receiving antiretroviral therapy with a ritonavir-boosted PI and two NRTIs continuously for ≥ 6 months preceding the screening visit
- Plasma HIV-1 RNA concentrations (at least two measurements) at undetectable levels for ≥ 6 months prior to the screening visit and HIV-1 RNA 50 copies/mL measured at two consecutive time points after first achieving HIV RNA 5 x ULN eligible if serum lipase ≤ 5 x ULN)
- Adequate renal function (estimated glomerular filtration rate ≥ 70 mL/min according to the Cockcroft-Gault formula)
- Males and females of childbearing potential must agree to utilize highly effective contraception methods (two separate forms of contraception, one of which must have been an effective barrier method, or been nonheterosexually active, practice sexual abstinence, or have a vasectomized partner) from screening throughout the duration of the study period and for 30 days following the last dose of study drug.
- Age ≥ 18 years
- Life expectancy ≥ 1 year
Exclusion Criteria
- A new AIDS-defining condition diagnosed within 30 days prior to screening except cluster of differentiation 4 (CD4) cell count and/or percentage criteria
- Females who are breastfeeding
- Positive serum pregnancy test (female of childbearing potential)
- Proven or suspected acute hepatitis 30 days prior to study entry.
- Current alcohol or substance abuse judged by the Investigator to potentially interfere with subject compliance.
- History of malignancy within 5 years prior to study entry or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, noninvasive cutaneous squamous carcinoma
- Active, serious infections requiring parenteral antibiotic or antifungal therapy within 30 days prior to baseline
- Anticipated need to initiate contraindicated drugs during the study, including drugs not to be used with FTC, TDF, RPV; or subjects with known allergies to the excipients of FTC/RPV/TDF STR tablets or Truvada® tablets
- All investigational drugs
- Medications and use of herbal/natural supplements excluded or to be used with caution while participating in the study, including those not to be taken with Viread®, Emtriva®, Truvada, and Rilpivirine.
- Participation in any other clinical trial without prior approval from the sponsor was prohibited while participating in this trial
- Treatment with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening, or expected to receive these agents or systemic steroids during the study
- History of liver disease, including Gilbert's Disease
- Any other clinical condition or prior therapy making the subject unsuitable for the study or unable to comply with the dosing requirements
Data sourced from ClinicalTrials.gov (NCT01252940). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.